ARCB vs HURN

ArcBest Corporation's Piotroski F-Score of 4/9 indicates weak financial health, signaling deterioration in operational efficiency and profitability. The absence of an Altman Z-Score raises concern about potential distress risk, especially given a current ratio of 0.95 and quick ratio of 0.79, both below safe thresholds. Despite a seemingly attractive forward P/E of 11.68, the company exhibits negative revenue growth (-2.90% YoY) and severe earnings declines (YoY EPS down 72.9%), undermining long-term sustainability. The Graham Number of $58.46 suggests a defensive fair value, yet the stock trades at $84.87—over 44% above this benchmark—indicating significant overvaluation. Analysts' 'buy' recommendation appears misaligned with deteriorating fundamentals.

HURN exhibits a concerning divergence between its current market price ($120.58) and its deterministic value markers, with a Piotroski F-Score of 4/9 indicating only stable health and a Graham Number of $64.91 suggesting significant overvaluation. While the company has a stellar track record of earnings beats, current YoY earnings growth is negative (-6.5%) despite revenue growth. This fundamental weakness is compounded by a 0/100 technical trend and bearish insider activity, suggesting the stock is currently priced for perfection in a declining trend.